Cibus reported a 35% year-to-date revenue increase, driven by its Sustainable Ingredients program, but total quarterly revenue was modest at $1 million. The company updated its guidance for initial commercial rice launches in Latin America to 2028, which could be a short-term negative, though it highlighted cost reductions and a favorable regulatory environment.
Cibus's Q2 2026 earnings call revealed a mixed bag for investors. While the company achieved a 35% year-to-date revenue increase, primarily from its Sustainable Ingredients program, the total quarterly revenue remained low at $1 million. A significant update was the delay of initial commercial rice launches in Latin America to 2028, which could temper short-term growth expectations and might be viewed negatively by the market. However, the company also demonstrated strong cost discipline, reducing R&D and SG&A expenses by nearly $5 million year-over-year, and highlighted a favorable regulatory environment in the EU for gene-edited crops, which presents a long-term opportunity. Traders should consider the tension between the delayed product launch and the positive cost control and regulatory tailwinds.